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Materials and methods. We evaluated all the patients who received a High Dose Rate (HDR) boost in our department
between October 2008 and September 2012. All of them were treated with external radiotherapy to the whole breast
before the boost. We evaluated acute and long term toxicity. Then, we compared the results between the women treated
in a conventional way versus hypofractionated patients. Prescription dose was based on the modiﬁed Paris dosimetry
treatment.
Results. We treated 379 boosts. 67.3% were hypofractionated and 32.7% were conventional treatments. 50.4% were right
breast cancers and the tumor bed was localized in upper external quadrant in 37.5% of patients. 59.9% received an 8Gy
boost. The mean implant volume (isodose of the 90% of the prescribed dose) was 8.68 cm3. Regarding toxicity, our results
do not differ much more than the presented in literature. We have less than 5% acute toxicity in terms of infection,
bleeding or acute pain. Chronically, most of the patients experience different grades of pain associated to ﬁbrosis, but it
doesn’t inﬂuence their daily lives in the majority of them. No grade 3 or 4 toxicity was reported. If we compare the results
between the groups (conventional and hypofractionated), we did not ﬁnd any statistically signiﬁcant difference in terms of
toxicity.
Conclusion. HDR-BRT is a safe and not much toxic way to administer the boost over the tumor bed in patients in indication. The
ﬁnal toxicity outcomes are not inﬂuenced by the fractionation of the previous whole breast treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.029
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Introduction. Adjuvant vaginal brachytherapy in gynaecological cancer alone or combined with EBRT is a standard procedure. The
vaginal brachytherapy HDR alone with 192 Ir is a technique with minimal side effects, can be performed in an outpatient. In
patients with limited disease in endometrial, vaginal and cervix uterine. The aim of our study is to describe our experience with
vaginal brachytherapy alone.
Materials and methods. We retrospectively analyzed 130 patients diagnosed with endometrial, vagina and cervix cancer. Between
January 2008 and January 2013. Treated with brachytherapy alone. We performed a descriptive study of our patients.
Results. 130 patients mean age 63.5 (32–85). 93.8% with endometrial cancer, cervix 4.6% and 1.5% vaginal cancer. Distributed
under the current classiﬁcation of FIGO. The mean follow-up 34.7 months (7–65), 90% adenocarcinoma, and 96.9% G1–G2. Mostly
without lymphovascular inﬁltration. Treated with postoperative vaginal brachytherapy alone, mean dose 24.2Gy (24–40), mean
of 6 fractions. Delimiting organs at risk as the bladder and rectum, with a mean dose of 11.8% and 7.8% respectively. 41.5% had
some degree of mucositis, of these only 3% were G3. In 2.3% of cases occurred surgical scar dehiscence during treatment. 96.9%
live free of disease, free of symptoms in 85.4%. 12.3% have some degree of dyspareunia or vaginal stricture. Only one patient was
treated in a palliative way for an unresectable tumour, staying without illness until date. 1 death for a no speciﬁc cancer reason.
Only 4 patients had recurrence (3.1%), 2 in the lung and 2 locally.
Conclusions. In our series, the recurrence rate is low, but we have found a relation between pathological stage and tumour grade.
Not with tumour size. Vaginal brachytherapy adjuvant to surgery in patients with early stage gynaecologic tumours and low
grade offers excellent overall survival and disease-free with very low toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.030
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Esophageal cancer (EC) is a rare tumor, very virulent and rarely curable. 50% of patients have metastatic disease at diagnosis and
50% have advanced locoregional disease. Advanced EC is a poor progression-free survival (PFS) in most of patients. Therefore the
treatment intention is palliation rather than curative. High dose rate intraluminal brachytherapy (HDR-ILBRT) allows quick and
lasting palliation and increase local control rates associated with radiochemotherapy (RCHT) in unresectable or advanced EC. The
aim of our study is evaluate symptomatic relief (pain, dysphagia) and local control in terms of PFS in unresectable or advanced
EC treated with HDR-ILBRT. Analyze secondary toxicities and the need for new treatment for recurrent dysphagia. We evaluated
between 2008 and 2012, seven patients diagnosed with unresectable or advanced EC who underwent HDR-ILBRT in our service.
Three of seven patients were treated with palliative brachytherapy (BT) and four received BT associated with RCHT (Boost).
The average dose prescribed for both treatments was 10Gy in 2 fractions, one per week. The variables studied were dysphagia
improvement, pain relief, secondary toxicities, new treatment for recurrent dysphagia and local progression-free survival in
patients treated with BT associated with RCHT. We observed that pain was relieved in all cases, dysphagia improvement in six
of them and only one required PEG. The most common acute toxicity was esophagitis G1 keeping one of them NGT after BT.
There was no bleeding or perforation. Esophageal stricture appeared as late toxicity in one patient at 5 months of completing
treatment. No endoscopic approach was necessary after BT. The mean local PFS time was 4 months for those treated with BT
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associated to RCHT. In conclusion, the esophageal BT is an effective alternative for symptomatic relief and improved long-term
dysphagia in advanced or unresectable EC and may improve locoregional control when is used as Boost.
http://dx.doi.org/10.1016/j.rpor.2013.03.031
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Purpose. To evaluate, the improvement in accuracy and quality prescription, using three-dimensional image-based treatment
planning and dosimetry for vaginal brachytherapy.
Methods and materials. For three-dimensional planning, ﬁfty-two patients with endometrial or cervical cancer, were simulated
by computed tomography. The bladder, rectum, sigmoid, and small bowel (OARs) were contoured, and prescription dose was
generated for 6 fractions of 450 cGy in 34 patients (65.3%). Associated to external beam radiation therapy in 18 (34.6%) 3 fractions
of 400 cGy. Cylinder diameter was 3 cm in 50 patients (96.2%) and 2.5 cm in 2 (3.8%). Vaginal thickness was estimated with three
3D measures. Dosimetry was calculated prescribing to a line of parallel points to the cylinder surface, including curved area. A
dose-volume histogram analysis was performed in all patients.
Results. The median age was 64 years. Median vaginal thickness was 4.5mm (range 3–5). Dose was prescribed to 3mm (2 p),
4mm (20 p) and 5mm (30 p). In 42.3% (22/52) the prescription depth was different from the standard. If standard prescription
(5mm) is used, there is an overdose of 7% in patients with vaginal thickness of 4mm, and 15% if 3mm. Median DEQ 2Gy per
fraction (OARs) values were: bladder 277 cGy. (135–415), rectum 329 cGy (198–462), and sigma 267 cGy (70–402). The DEQ 2Gy
for exclusive brachytherapy (6 fractions) to (OARs) were: bladder 2115 cGy (1285–3560), rectum 2760 cGy (1536–4244) and sigma
2025cGy (739–3386).
Conclusions. Image-based 3D treatment planning for brachytherapy allows to visualize theprecise placement of cylinder in relation
to vaginal surface, and plan personal treatment with the knowledge of doses at (OARs). And in case of additional external beam
radiotherapy, calculate the DEQ 2Gy per fraction for OARs. In 42% of patients, the prescription dose to 5mm would have been
excessive, with unnecessary overdose to vaginal wall, that might compromise good functional results.
http://dx.doi.org/10.1016/j.rpor.2013.03.032
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Purpose. To determine the role of interstitial high-dose-rate brachytherapy (HDR ITB) in themanagement of high risk gynecological
cancer.
Methods. Sixty-two patients with cervical (n=24), endometrial (n=22) and vulvovaginal tumors (n=16) were treated with HDR-ITB
for recurrent tumor after prior radiation (n=14). Unirradiated cases (n=48) were treated with external irradiation (or chemoradi-
ation) and HDR ITB to planned EQD2 doses of 67.6–79.3Gy, and previously irradiated patients received HDR ITB alone to planned
EQD2 doses of 46.7Gy.
Results. With a median follow-up of 3.7 years (range 0.2–10.0), grade ≥3 late events were seen in 7.1% and 16.7% of the previously
irradiated andunirradiated patients, respectively. Grade≥2 bladder eventswere related to younger age (p=0.014), recurrent status
(p=0.025), and 2 cm3 brachytherapy bladder dose (p=0.017) in multivariate analysis. Grade ≥2 rectal events were associated with
vaginal site (p=0.043) and 2 cm3 brachytherapy rectal dose (p=0.001) in multivariate analysis. Five-year locoregional control rates
in previously irradiated cases and unirradiated cases were 55% and 67.5%, respectively. Locoregional control was inversely related
to implant size TV150 (p=0.001) and to brachytherapy EQD2 to CTVD90 (p=0.008) in multivariate analysis. Finally, 5-year overall
survival rates in previously irradiated cases and unirradiated cases were 40% and 57%, respectively.
Conclusions. HDR provides durable control with reasonable toxicity in this patient population with an unfavorable prognosis
and yields long-term disease-free survival in a signiﬁcant percentage of patients. Image-based dosimetric surrogates should be
closely analyzed to minimize long-term toxicity and maximize disease control.
http://dx.doi.org/10.1016/j.rpor.2013.03.033
